Previously, the company expected full-year Group revenue to be in the range of $2.0 billion to $2.1 billion in constant currency and Generics revenue around $670 million in 2017. Core profit before tax was $148 million, compared with $147 million last year. Profit attributable to shareholders increased 19% to $69 million, while core attributable profit of $109 million was in line with last year. EBITDA grew 9 percent to $211 million and core EBITDA increased 2 percent to $215 million. Revenue increased 1 percent to $895 million from $882 million last year.

Source: The North Africa Journal August 17, 2017 09:22 UTC